EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
MAb Aggregation: A Problem Within the Biopharmaceutical Industry
Associate Professor, Trinity College Dublin, Ireland
Educated at Seoul National University UC Berkeley and Purdue University with postdoctoral research at the University of Oxford KH Mok specializes in utilising biomolecular NMR spectroscopy to protein foldingmisfoldingaggregation research Coauthor of publications in Nature Nature Communications Nature Immunology PNAS and others he currently serves as a Eureka Independent Evaluation Panel member tec...
Articles
Incipient Biopharmaceutical Claims of Milk Derived Exosomes
Exosomes are bilayer nanoextracellular vehicles EVs that areproduced by endocytosis in mammalian cells Under physiological conditions they are involved in intercellular communication viaproteins lipids and RNAs With a size distribution of nm exosomes have been identified in various biofluids
Research Insights
A Proteomic Perspective and Involvement of Cytokines in SARS-CoV-2 Infection
Infection with the SARSCoV virus results in manifestation of several clinical observations from asymptomatic to multiorgan failure
Case Studies
Heat Stable Insulin Analogues (Zinc-complexed and Zinc-free)
Challenge Insulin is used to treat various forms of diabetes mellitus Patients with type I diabetes mellitus depend on external insulin most commonly injected subcutaneously for their survival because of the deficiency of the hormone Insulin is typically deli
Techno Trends
First-of-its-Kind Digital Therapeutic BNT200 Discovered
Blue Note Therapeutics discovered firstofitskind prescriptiononly digital therapeutic BNT for the treatment of anxiety and depressive symptoms in adults patients with acute myeloid leukemia AML hospitalised for a regimen of highintensity induction chemotherapy BNT is a software as a medical device SaMD designed t treat anxiety and depressive
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Nanotechnology as a Potential Therapeutic Strategy in Breast Cancer Management
Mr. Rahul Pal (Young Scientist), Ass. Prof. Department of Pharmacy, Jagannath University, Jaipur, holds B. Pharm, M. Pharm (Pharmaceutics), and PhD* at Chitkara University. He has authored 50+ publications, 8 textbooks, 12 edited book, secured 38 patents, 3 copyrights, received the Young Researcher Award (2025), and actively contributes as reviewer, editor, and speaker in national and international academic forums.
The Past, Present, and Future of Sickle-cell Disease Registries: Findings from a Global Review
Sam is an Associate Director in Patient-Centered Research at Vitaccess, providing direction and oversight across their health economics and outcomes research, patient-centered outcomes, and real-world evidence portfolio. Sam joined Vitaccess in 2018, after spending three years as a project manager within the PCO group at a leading contract research organisation.
Fatemeh is a Medical Writer at Vitaccess. She plays a key role in their digital real-world evidence studies, developing materials that range from client-facing deliverables through to content communicating the value and progress of studies to clinical experts, patient representatives, and participants.
Oktawia is a Research Associate at Vitaccess, contributing to their patient-reported outcomes and clinical outcome assessment projects and supporting the development, effective delivery, and quality of their real-world studies. Oktawia has experience in health research from previous roles involving healthcare technologies, a medical ventures accelerator, and her doctoral research studies.
Akosua is an Associate Consultant at Vitaccess, currently project managing a range of their longitudinal and cross-sectional real-world evidence studies. She has experience in developing evidence-generation strategies for clients, including gap analyses for health technology assessment submissions and the reimbursement of digital health technologies.
CAR-T Cell Therapy and NexCAR19
Dr Ashwini Kumar is presently working as an Assistant Professor in the Biotechnology and Bioinformatics Area at NIIT University, Neemrana (Rajasthan), India. Biomaterial science has been the main focus of Ashwini's research, particularly in the area of cutting-edge drug delivery techniques. His research's intended uses are developing minimally invasive and non-invasive medication delivery strategies to improve patient compliance and outcomes. Two other area that pique his curiosity are tissue engineering and diabetes. Ashwini is the author for twenty-two journal articles published in both domestic and foreign journals, eight book chapters, a book. In addition, he has a patent for his PhD work. He has been asked to participate in juries and speak on several national scientific venues. He has been working as a reviewer for reputable journals published by Frontiers, Elsevier, and Wiley. He is a guest editor of Frontiers in Medical Technology, a focused journal from Frontiers Publications, and a regular reviewer of Materials and Design, Elsevier. He is a life member of Asian Polymer Association.
Combating the FWA Menace
Ravi Iyer is a visionary and innovative executive with diverse experience in leading and managing product delivery, client implementation, customer service, and operations with direct responsibility for multimillion-dollar budgets. He has extensive experience delivering across multiple disciplines, including Data Management, Data Governance, Cloud Architecture, Advanced Analytics, Master Data Management, Digital Products, and Digital Transformation. Excellent communicator who works collaboratively to deliver technology strategies and value added solutions that meet the needs of all business functions. Ravi is currently the technology executive and Senior Director at Elevance Health Inc.
Narasimha is result driven leader with vast experience in executing various PBM, Health care, Financial, and securities trading applications. Technical expertise in Big data, Cloud, Analytics, Mainframe, BPM, testing, and Data warehouse projects at esteemed organizations like Anthem, Tetrasoft, DST, HCL, Deutsche bank, and Atos Origin. He currently works as Solution Architect at Tetrasoft Inc. Narasimha has vast experience in Pre-sales, Project management, effective customer communication, Architect, Technical Lead, On-site coordinator, and business Analyst roles for various complex assignments across the globe.
Smart Polymeric Nanocomposites for Cancer Therapeutics
Saurabh Shivalkar is a research fellow at Department of Applied Sciences, IIIT Allahabad, India. He did his M. Tech (Biomedical Engineering) from IIIT Allahabad. He has recently filed patent and published multiple papers in the allied areas of biomedical engineering and nanobiotechnology.
Sneha Ranjan is currently pursuing M.Sc. (Biotechnology) at Department of Biotechnology of Babasaheb Bhimrao Ambedkar University, Lucknow. She has worked on projects such as purification and characterisation of enzyme, production of recombinant proteins for diagnostics and therapeutics. She is currently working on polymeric nanocomposites for cancer therapeutics.
press releasesRead more...
First FDA Breakthrough Therapy designation in PSMA PET imaging granted to Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer
Clarity PharmaceuticalsASX CU Clarity or Company a clinicalstage radiopharmaceutical company with a mission to develop nextgeneration products that improve treatment outcomes for patients with cancer is pleased to announce that
Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program
Pfizer Inc NYSE PFE and Blackstone Life Sciences Blackstone today announced a strategic cofunding agreement under which funds managed by Blackstone will pay up to a total of billion of development
Circio and Solid Biosciences enter collaboration to evaluate circVec and POLARIS-101 technology for Genetic Heart Disease
Circio Holding ASA OSE CRNA a biotechnology company developing novel circular RNA expression technology for gene and cell therapy today announces a research collaboration with Solid Biosciences Inc
EirGenix and Merck enter Partnership to Strengthen Global Biologics Development Through Integrated BioReliance® Testing and Regulatory Support
EirGenix Inc and Merck have signed a nonlegally binding memorandum of understanding MOU to support EirGenixs IND and BLA enabling biologics pipeline development The MOU outlines Merck as one of EirGenixs preferred contract testing services vendors providing comprehensive BioReliance services
ProBio Enters Exclusive Global Licensing Agreement with AbTis to Develop Next-Generation ADC Asset
ProBio a global contract research development and manufacturing organization CRDMO today announced that it has entered into an exclusive global licensing agreement with AbTis Co Ltd
AGC Biologics partners with Child’s Cure Genetic Research to pursue mRNA-based therapeutic for severe epileptic disorder
In a world where patients with CDKL deficiencies can suffer to epileptic seizures a day a contract biopharmaceutical manufacturer and a parentfounded foundation will partner on earlystage
EventsRead more...
11 - 13
Nov 2026Frontiers in Cancer Science 2026
One Farrer Hotel,1 Farrer Park...
16 - 17
Nov 2026Analytics for Smarter Decisions in Pharma
London, UK
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
26 - 28
Nov 2026One Health Conference 2026
Thapar Institute of Engineerin...
01 - 03
Dec 2026Pharmaceutical Launch Excellence Summit
Novotel Amsterdam City, Nether...
01 - 03
Dec 202610th Antifibrotic Drug Development
Boston, MA at the Hotel Common...
02 - 04
Dec 2026Genome Informatics 2026
Wellcome Genome Campus, UK
LATEST NEWSRead more...
Immuneering Enters into Collaboration with Astellas to Evaluate Combination Therapies for Pancreatic Cancer
Immuneering has entered into a clinical trial collaboration and supply agreement with Astellas Pharma to evaluate investigational combination therapies for patients with pancreatic cancer
Eppendorf Invests €40 Million in New Manufacturing Facility in Penang, Malaysia
Eppendorf has started construction of a new manufacturing facility at Bandar Cassia Technology Park in Penang Malaysia
Lilly Invests US$3.5 Billion in New Manufacturing Facility for Obesity Medicines in Pennsylvania
Eli Lilly and Company has started construction of a US billion manufacturing facility in Lehigh Valley Pennsylvania as part of its plans to expand medicine production in the United States The new site is one of manufacturing facilities
Natera Enters into Collaboration with Incyte for Phase II Trial in Colorectal Cancer
Natera a precision medicine company has entered into a clinical collaboration with Incyte to support a new Phase II study evaluating an investigational treatment for colorectal cancer CRC
Shionogi Enters into Licence Agreement with Link for Antibiotic Cefiderocol
Shionogi has entered into a licence agreement with Link Healthcare Singapore to develop and commercialise cefiderocol in Singapore and Malaysia
IDEL Therapeutics Partners with Daiichi Sankyo to Develop Multi-Drug Conjugates for Solid Tumours
IDEL Therapeutics has entered into a global research collaboration with Daiichi Sankyo to evaluate a multidrug conjugate MDC using iDELs synthetic shuttle platform for the treatment of selected solid tumours The multiyear collaboration will focus on the preclinical evaluation of a new class of MDCs...


